LLY Eli Lilly
- Official Name: ELI LILLY AND COMPANY
- Headquarters: Lilly Corporate Ctr, Drop Code 1094, INDIANAPOLIS, IN, 46285 US
- CEO: David A. Ricks
- Website: lilly.com
- Key Investor: PNC FINANCIAL SERVICES GROUP, INC. | 10.68%
- Dedicated Investor: LILLY ENDOWMENT INC | 100%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1 | Won by 1.485 | 0.622 - (0.863) | ||
| 2025-07-22 | 2 | Lost by 1.727 | 1.457 - 3.184 | ||
| 2025-07-29 | 3 | Lost by 4.303 | (2.272) - 2.031 | ||
| 2025-07-29 | 2R | Lost by 6.678 | (5.321) - 1.357 | ||
| 2025-08-05 | 4 | Won by 2.977 | 2.823 - (0.154) | ||
| 2025-08-07 | 1R | Lost by 13.781 | (10.430) - 3.351 | ||
| 2025-08-12 | 5 | Won by 0.443 | 0.329 - (0.114) | ||
| 2025-08-19 | 6 | Won by 8.814 TOTW | 11.298 - 2.484 | ||
| 2025-08-26 | 7 | Won by 1.644 TOTW | 4.545 - 2.901 | ||
| 2025-09-02 | 8 | Lost by 3.542 | (0.113) - 3.429 | ||
| 2025-09-03 | 1R | Won by 1.312 | 0.243 - (1.069) | ||
| 2025-09-09 | 9 | Won by 2.208 | 2.208 - 0.000 | ||
| 2025-09-16 | 10 | Won by 1.163 | 2.318 - 1.155 | ||
| 2025-09-17 | 2R | Won by 0.260 | (0.577) - (0.837) | ||
| 2025-09-23 | 11 | Lost by 2.279 | (2.638) - (0.359) | ||
| 2025-09-30 | 12 | Won by 2.733 | 2.132 - (0.601) | ||
| 2025-10-01 | QF | Won by 7.240 | 7.918 - 0.678 | ||
| 2025-10-07 | 13 | Won by 10.569 TOTW | 9.513 - (1.056) | ||
| 2025-10-14 | 14 | Lost by 1.954 | (3.845) - (1.891) | ||
| 2025-10-15 | SF | Won by 0.503 | 1.869 - 1.366 | ||
| 2025-10-21 | 15 | Lost by 0.029 | (1.548) - (1.519) | ||
| 2025-10-22 | F | Won by 1.225 | 1.678 - 0.453 |
Latest News
Foundayo’s Early Growth Is Raising Lilly (LLY)’s Revenue Expectations. But Can It Outrun Pricing Pressure?
Eli Lilly and Company (NYSE:LLY) received a modest price target raise on September 18 from Guggenheim. The brokerage increased its target to $1,284 fr...
Here's Where Wall Street Analysts See Eli Lilly's Share Price Going
Eli Lilly's share price climb has decelerated in 2026.
Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become
Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.
A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved
Key Stats for Eli Lilly StockCurrent Price: $1,183. 46Target Price (Mid): ~$2,060Street Target: ~$1,325Potential Total Return: ~74%Annualized IRR: ~14...
Eli Lilly (LLY) vs. Novo Nordisk (NVO): Has the GLP-1 Race Changed the Moat?
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market’s vi...
Eli Lilly (LLY) Wins Two FDA Approvals And A $3.35 Billion Drug Alliance
Eli Lilly (NYSE:LLY) received FDA approval for Olumiant to treat pediatric patients with severe alopecia areata. The FDA also cleared once weekly insu...
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Olumiant (baricitinib), a once-daily pill,...
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the
How to make sense of 7% mortgage rates and Oracle's AI data center disruption
In this episode of Market Hang, Turney Duff and his panel of experts weigh in on Oracle's (ORCL) recent data center hiccups, high mortgage rates,...
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
Healthcare stocks edged higher Friday afternoon, with the NYSE Healthcare Index and the State Street
Eli Lilly Receives FDA Approval For Olumiant In Pediatric Patients Aged 12 And Older With Severe Alopecia Areata
FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with sev...
Is LLY Stock Cheaper Than It Looks?
At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with s...
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually recei...
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
The latest installment in BioPharma Dive’s data visualization series features a closer look at Novo's stock performance and the recent run of f...
Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case
All three major US stock indexes were edging higher in midday trading Friday as Treasury yields rema
2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not onl...
Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal
(Updates to add Eli Lilly's response in the fifth and sixth paragraphs.) Nektar Therapeutics (NK
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds
A federal jury in California has awarded Nektar Therapeutics Inc. (NASDAQ:NKTR) $90 million in damages, finding that Eli Lilly and Co. (NYSE:LLY) brea...
LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D
Eli Lilly gets FDA approval for once-weekly Onswik, offering adults with type II diabetes a more convenient alternative to daily basal insulin.
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly
Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) shares rose 3.6% in premarket trading Friday following a jury verdict awarding the company $90 mill...
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued tw...
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sect
91-year-old investor sees healthcare titan doubling in 3 years
The billionaire Home Depot co-founder has held the stock since 1977. Here’s where he thinks it’s going.
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
The biotech player could eventually rival big pharma companies.
Novo Signs $1.3 Billion Nanexa Deal for Long-Acting Drugs
Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s Nanexa AB, the latest in a string of small acquisition...
Nektar Therapeutics Announces That Jury Found Lilly Did Breach Implied Covenant Of Good Faith And Fair Dealing Under License Agreement; Company Awarded $90M In Damages Plus Interest
On September 24, 2026, the jury returned a verdict finding that Lilly breached the implied covenant of good faith and fair dealing in the License Agre...
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug ma...
Eli Lilly (LLY) Stock Is Up, What You Need To Know
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after The U.S. Food and Drug Administration approved...
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuation...
Eli Lilly breaks ground on $6.5B Houston manufacturing plant
Bechtel’s manufacturing and technology business unit is supporting the project, according to a job posting from the Reston, Virginia-based general c...
Medicare just handed Eli Lilly a massive weight-loss win
As Medicare Bridge participation surges, Novo Nordisk’s share of those new patients is drawing attention.
Lilly Jumps 3.64% While a $100 Billion Obesity Race Crowds In
New pills, injections and maintenance regimens broaden patient choice while raising the durability test for market leaders.
Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's wide...
Eli Lilly and InnoCare sign drug discovery deal worth up to $3.35B
Lilly will pay $100 million upfront to work with the Beijing-based biotech on as many as five undisclosed drug targets
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's t...
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions
AC Immune maintains a "Buy" rating, driven by positive 100-week safety and immunogenicity data for ACI-7104. Click to read in detail about A...
Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare
InnoCare, which already has three approved therapies, describes itself as a biopharma focusing on cancer and autoimmune disease treatments.
Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight
Treatment of chronic kidney disease (CKD) focuses on slowing disease progression toward kidney failure, reducing cardiovascular risk, and addressing c...
Lilly’s latest China drug deal; Immunovant’s setback in lupus
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Ve...
8 Of 11 Sectors Fall In Thursday Trading As Leaders Split
Three sectors are higher and eight are lower in Thursday’s regular session, with growth, cyclical and defensive sectors each represented among the t...
S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today
Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.
Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact
Eli Lilly secured FDA approval for its once-weekly insulin Onswik and announced a $3.25 billion research partnership with InnoCare Pharma.
BigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design
SAN MATEO, Calif., September 24, 2026--BigHat Biosciences, a clinical-stage, AI-driven protein therapeutics platform company, today announced the comp...
ISPE Announces its 2026 ISPE Annual Meeting & Expo Keynote Speakers
The International Society for Pharmaceutical Engineering (ISPE) has announced its planned keynote speakers for its largest event of the year, the 2026...
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Novo Nordisk A/Sâs 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.
The FDA Approves Eli Lilly's Onswik (Insulin Efsitora Alfa-gobe) For Type 2 Diabetes
Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly ...
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment ...
Novo's new strategy hinges on something it can't manufacture: investor trust
Novo has now reached the point where it can broaden its ambitions again, CEO Mike Doustdar told CNBC, but investors remain unconvinced.
Bill Ackman Calls AI’s Rare-Disease Breakthrough ‘Incredible’ After Model Finds Drug Combination for Dying Patient
Bill Ackman highlighted a case where AI identified an untried drug combination that helped a dying rare-disease patient recover.
Could Retatrutide Be Worth $10 Billion to Eli Lilly?
The company continues to dominate the weight loss market.
Lilly Slips as $6.5 Billion Plant Backs Oral GLP-1 Scale
Houston will produce Foundayo ingredients, linking manufacturing capacity directly to Lilly's planned global rollout.
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 resu...
What Is AbbVie No Longer Telling You?
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned th...
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosing.
What Is The Best Case For Pfizer Stock?
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy t...
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceut...
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportuniti...
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
Viking Therapeutics' shares jump 36% as VK2735 maintenance data show most weight loss is preserved with less-frequent dosing.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transac...
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset paten...
Viking Therapeutics: 'Strong Buy' On Injectable VK2735 Maintenance Data And Treatment Optionality
Viking Therapeutics maintains a 'Strong Buy' rating, driven by positive phase 2 and maintenance data for its dual GLP-1/GIP agonist VK2735. ...
Lilly stopped showing its phase 1 pipeline. Is it playing R&D chess?
Lilly no longer publicly lists its earliest clinical programs. The move could buy the pharma giant time to test, kill and reposition drugs while compe...
AutoZone (AZO) Posts Strong Earnings, But Is the Stock Ready to Rebound?
On September 22, AutoZone, Inc. (NYSE:AZO) reported results for its fourth quarter, which covered 16 weeks and ended August 29, 2026. The company deli...
Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets
Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock...
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
Appointments support ProQR’s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipel...
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva
Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and...
Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seniors: 'Growing Week on Week'
Eli Lilly and Co.‘s CEO Dave Ricks announced a significant increase in the use of GLP-1 treatments among seniors, following Medicare’s July decisi...
Viking Therapeutics Soars as Weight-Loss Drug Trial Addresses GLP-1 Weakness
Research has shown the adherence rates of patients on GLP-1 therapies can fall as low as 27% after one year.
Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone
Home Depot co-founder Ken Langone says Eli Lilly could hit $2,000 in 3 to 4 years, challenging Home Depot as his top portfolio holding.
Obesity titan could shake up Lilly and Novo after astonishing trial
The San Diego company’s flexible dosing results could carve out real market share in the obesity drug race.
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.
Eli Lilly CEO reveals astonishing shift in GLP-1 pill market
Medicare coverage opens the obesity pill market to millions more Americans.
Lilly Rises Higher as Viking Preserves Up to 90% Monthly
Less-frequent injections could challenge chronic-treatment economics long before Viking reaches the market.
Novo Nordisk Just Made a Surprising Move Beyond Weight Loss
The company aims to launch more than five potential blockbuster drugs by 2030.
Should Eli Lilly (LLY) Investors Watch Its $6.5 Billion Houston GLP 1 Buildout?
Eli Lilly (NYSE: LLY) has started construction on a US$6.5b manufacturing facility in Houston to produce its oral GLP-1 drug Foundayo. The new site is...
Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems
Novo Nordisk is dealing with headwinds, but was its name really one of the big problems?
VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win
The San Diego company is trying to carve out a place beside Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy with a dual GLP-1/GIP drug that can be ...
Beyond Eli Lilly and Novo Nordisk: Rising Obesity Drug Stocks to Watch
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.
Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study
RHHBY's enicepatide cut HbA1c and body weight in a phase II study, strengthening its obesity ambitions as it advances the drug into phase III.
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely register...
Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?
When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
NVO's CagriSema delivers greater weight loss than Eli Lilly's tirzepatide in T2D and 21% weight loss in obesity, strengthening its late-stag...
Eli Lilly Breaks Ground on $6.5B Generation Park Facility
A $6.5B Eli Lilly biomanufacturing facility broke ground at Houston’s Generation Park, Texas’ largest pharmaceutical investment to date.
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of ...
His Bet On Home Depot Made Ken Langone A Billionaire. Now He Sees Eli Lilly Stock Hitting $2,000
Ken Langone built a fortune betting on Home Depot decades before anyone called it a sure thing, and now he says another stock in his portfolio is givi...
Could You Have Seen Merck Stock's Pipeline Run Coming?
Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Joh...
Viking Therapeutics Stock Surges 30%. It Could Challenge Lilly and Novo’s Obesity Empire.
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.
Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer
The FDA fully approves Eli Lilly's Inluriyo and Verzenio combination for advanced breast cancer, doubling progression-free survival.
Roche Obesity Drug Enicepatide Delivers 15.5% Weight Loss in Phase 2 Diabetes Trial
Roche (USOTC:RHHBY) has reported positive results from a mid-stage clinical trial of its experimental obesity treatment enicepatide, with patients who...
Why Is JNJ Stock Beating Rivals That Grow Faster?
Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growt...
Eli Lilly CEO Dave Ricks: 70% of new Medicare GLP-1 patients on Lilly drugs
CEO Dave Ricks told CNBC that 700,000 seniors have started weight loss treatments since Medicare coverage launched in July
Eli Lilly CEO Delivers Urgent Message on the Company's Next Big Weight-Loss Pill
Eli Lilly Stock Gets Powerful Boost From Foundayo as Oral Weight-Loss Pill Gains Ground
Eli Lilly Just Got a Big Boost From Medicare's GLP-1 Expansion
About 700,000 seniors have started GLP-1 treatments since Medicare coverage began in July.
VKTX Stock Spikes 38% Premarket: Viking’s VK2735 Shows Promise For Weight-Loss Maintenance
Viking Therapeutics’ experimental obesity drug showed it could preserve most patients’ prior weight loss with less frequent dosing.
Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase
SAN DIEGO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challen...
Novo targets blockbuster-heavy 2030 but share slump signals unease
Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
Viking Therapeutics and Roche both reported positive obesity drug data early Tuesday. Viking stock surged. Eli Lilly and Novo fell.
Eli Lilly’s Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon
Eli Lilly just posted a quarter that crushed estimates on every major metric, yet the stock has spent the past month getting punished anyway. One of W...
TD Cowen Reiterates Buy on Eli Lilly, Maintains $1250 Price Target
TD Cowen analyst Steve Scala reiterates Eli Lilly (NYSE:LLY) with a Buy and maintains $1250 price target.